{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","spread":"9.7","value":"15.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"End of induction"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"6.2","value":"13.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"End of therapy"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"2.9","value":"7.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"6-months off therapy"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"12-months off therapy"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"6.5","value":"9.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"24-months off therapy"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"36-months off therapy"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"48-months off therapy"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"60-months off therapy"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Growth hormone secretion was measured in consenting intermediate risk patients at the end of induction therapy, the end of all therapy, and at 6, 12, 24, 36, 48, and 60 months off therapy. Mean growth hormone secretion values are reported by assessment time point. Please note the small numbers of participants with available data.","dispersionType":"Standard Deviation","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.","id":"OG002","title":"High-Risk Group"}],"paramType":"MEAN","populationDescription":"Growth hormone secretion was measured in consenting intermediate risk patients. No Intermediate Risk patients had data available at 12, 36, 48, and 60 months off therapy.","reportingStatus":"POSTED","timeFrame":"End of induction therapy (approximately 16 weeks from start of treatment), end of therapy (approximately 48 weeks from start of treatment), and 6, 12, 24, 36, 48, and 60 months off therapy","title":"Growth Hormone Secretion","type":"SECONDARY","unitOfMeasure":"ng/mL"}